Latest news
ICYMI: EU Approves Upadacitinib for Severe Alopecia as US Review Remains Pending - Dermatology TimesDermatology Times · Thu, 06 Aug 2026 13:39:20 GMTWeekly Recap: Q2 revenue gain; EPS narrowed and Rinvoq EU nod for 12+ vitiligo - TradingViewTradingView · Mon, 03 Aug 2026 11:33:04 GMTAbbVie’s RINVOQ wins EU approval as first systemic treatment for vitiligo - Indian Pharma PostIndian Pharma Post · Sat, 01 Aug 2026 07:00:00 GMTAbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 07:00:00 GMTAbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo - PMLiVEPMLiVE · Fri, 31 Jul 2026 07:00:00 GMTAbbVie corrects FY26 adj EPS guidance to $13.87-$14.07 vs $14.08 est - scanx.tradescanx.trade · Fri, 31 Jul 2026 07:00:00 GMTPfizer's ritlecitinib advances to become first oral systemic therapy for nonsegmental vitiligo - AllSciAllSci · Thu, 30 Jul 2026 16:35:55 GMTEU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals - Pharmaceutical TechnologyPharmaceutical Technology · Thu, 30 Jul 2026 07:00:00 GMT